The pharmaceutical giant presented mid-stage trial data on the pill, muvalaplin, at the American Heart Association Scientific ...

State Medicaid programs for low-income families are the single biggest source of coverage, giving 31.6 million people access ...

The highest dose of an experimental pill developed by Eli Lilly dramatically lowered an inherited form of high cholesterol in ...

Arguably, no big pharma stocks have dominated the industry more over the last few years than Eli Lilly (NYSE: LLY) and Pfizer ...

The lawsuit is the second by a large drugmaker in recent days challenging how it provides required discounts to certain ...

The makers of Ozempic and Zepbound are fighting to stop compounded copies of their drugs. But it’s unclear whether they can ...

Lilly to Develop Two Targets Identified and Validated Using ’ AI-Enabled, All-in-Human CONVERGE® Platform — Demonstration of ...

A little more than a month after AstraZeneca jumped into the fray with the purchase of a rival heart drug candidate, Eli ...

Eli Lilly & Co. shares plunge 12.5% this month, worst since 2009, due to disappointing earnings and lowered guidance. The ...

The new mens range debuted at a VIP fashion show in Palm Beach last week, and will arrive in stores in February for the ...

Lilly’s muvalaplin is the first oral drug to show positive Phase II findings for Lp(a) reduction, eliciting up to an 86% drop ...

The trial met both primary endpoints, with tirzepatide showing a 38% decrease in heart failure outcomes compared to placebo.